| |
| |
|
| Insider
Information: |
Higgins John L |
| Relationship: |
Director |
| City: |
Palo Alto |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
3 |
|
| Direct
Shares |
2,806,928 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$49,664,092 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
2,806,928 |
|
|
| Total
Value |
$49,664,092 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
11
|
|
Stock
price went up :
|
0
|
5
|
| Stock
price went down : |
0
|
6
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -38.4%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Ligand Pharmaceuticals Inc |
LGND |
Director |
2022-12-28 |
417,695 |
2007-02-01 |
0 |
Premium* |
|
|
Techne Corp |
TECH |
Director |
2024-05-14 |
36,608 |
2013-10-31 |
0 |
Premium* |
|
|
OmniAb, Inc |
OABI |
Director |
2024-01-30 |
2,352,625 |
2022-11-01 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
• • – |
2021-02-05 |
4 |
AS |
$203.40 |
$11,119,239 |
D/D |
(54,666) |
286,030 |
0 |
% |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
• • – |
2021-01-25 |
4 |
AS |
$159.00 |
$7,950,000 |
D/D |
(50,000) |
235,310 |
0 |
% |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
• • – |
2021-01-27 |
4 |
AS |
$182.00 |
$7,280,000 |
D/D |
(40,000) |
243,422 |
0 |
% |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
• • – |
2018-08-16 |
4 |
AS |
$241.33 |
$5,190,261 |
D/D |
(21,507) |
88,919 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
• • – |
2018-01-19 |
4 |
AS |
$151.92 |
$4,318,902 |
D/D |
(28,099) |
134,200 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
• • – |
2018-01-24 |
4 |
AS |
$165.00 |
$3,712,500 |
D/D |
(22,500) |
111,700 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
• • – |
2018-08-17 |
4 |
AS |
$243.00 |
$3,157,299 |
D/D |
(12,993) |
88,919 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
• • – |
2018-05-15 |
4 |
AS |
$179.97 |
$2,232,491 |
D/D |
(12,405) |
107,419 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
CEO & President |
• – – |
2007-02-01 |
4 |
A |
$12.68 |
$1,902,000 |
D/D |
150,000 |
150,000 |
0 |
- |
|
| TECH |
Techne Corp |
Director |
– • – |
2018-08-23 |
4 |
S |
$187.92 |
$1,879,173 |
D/D |
(10,000) |
3,012 |
0 |
- |
|
| TECH |
Techne Corp |
|
– • – |
2020-11-06 |
4 |
S |
$298.98 |
$1,501,744 |
D/D |
(5,000) |
4,412 |
0 |
% |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
• • – |
2018-02-15 |
4 |
AS |
$157.03 |
$1,413,279 |
D/D |
(9,000) |
102,700 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
• • – |
2021-02-05 |
4 |
OE |
$10.05 |
$1,394,017 |
D/D |
114,666 |
346,030 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
• • – |
2017-06-09 |
4 |
AS |
$114.87 |
$1,378,440 |
D/D |
(12,000) |
139,171 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President & CEO |
• • – |
2014-02-12 |
4 |
AS |
$75.00 |
$1,265,625 |
D/D |
(16,875) |
111,099 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
• • – |
2021-01-27 |
4 |
OE |
$14.47 |
$1,236,400 |
D/D |
70,000 |
273,422 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
• • – |
2021-01-25 |
4 |
D |
$156.01 |
$1,160,870 |
D/D |
(7,441) |
243,422 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
• • – |
2016-03-07 |
4 |
S |
$102.44 |
$1,110,027 |
D/D |
(10,833) |
119,664 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
• • – |
2022-01-26 |
4 |
D |
$113.68 |
$1,050,744 |
D/D |
(9,243) |
349,018 |
0 |
- |
|
| TECH |
Techne Corp |
Director |
– • – |
2020-02-12 |
4 |
S |
$205.23 |
$1,026,133 |
D/D |
(5,000) |
4,021 |
0 |
% |
|
| TECH |
Techne Corp |
|
– • – |
2019-06-04 |
4 |
S |
$203.67 |
$1,018,346 |
D/D |
(5,000) |
3,526 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
• • – |
2018-02-15 |
4 |
D |
$157.18 |
$981,118 |
D/D |
(6,242) |
96,458 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President & CEO |
• • – |
2014-01-16 |
4 |
AS |
$64.00 |
$960,000 |
D/D |
(15,000) |
102,099 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
• • – |
2015-06-09 |
4 |
S |
$92.53 |
$928,809 |
D/D |
(10,000) |
126,044 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
• • – |
2018-08-30 |
4 |
S |
$258.25 |
$903,875 |
D/D |
(3,500) |
85,419 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
